As an investigational peptide, any legitimate clinical use involves a licensed provider, a prescription, and compounding through a licensed pharmacy
Survey and contrast radiographs and ultrasonography are primarily useful to rule out other causes for the clinical signs, such as foreign bodies
[2] Since then, several other GLP-1 agonists have been developed and approved for clinical use, including liraglutide (Victoza), dulaglutide (Trulicity), semaglutide (Ozempic and Wegovy), and Tirzepatide (Mounjaro and Zepbound)
The peptide's circulating half-life is short (minutes to hours), but the transcription factor cascades it triggers persist for days
Stage I is divided into stages IA and IB
The absence of effect is total at the dose of 77.5 M / kg for which the synergistic effect with respect to L-carnitine has been observed